138 related articles for article (PubMed ID: 32483610)
1. Preclinical efficacy of humanized, non-FcγR-binding anti-CD3 antibodies in T-cell acute lymphoblastic leukemia.
Tran Quang C; Zaniboni B; Humeau R; Lengliné E; Dourthe ME; Ganesan R; Singh S; Scheer JM; Asnafi V; Ghysdael J
Blood; 2020 Sep; 136(11):1298-1302. PubMed ID: 32483610
[TBL] [Abstract][Full Text] [Related]
2. Targeting the TNF/IAP pathway synergizes with anti-CD3 immunotherapy in T-cell acute lymphoblastic leukemia.
Ávila Ávila A; Nuantang K; Oliveira ML; Druillennec S; Zaniboni B; Lengliné E; Asnafi V; Ghysdael J; Tran Quang C
Blood; 2024 May; 143(21):2166-2177. PubMed ID: 38437728
[TBL] [Abstract][Full Text] [Related]
3. Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic haematopoietic stem cell transplantation.
Chan TSY; Sim JPY; Kwong YL
Ann Hematol; 2017 Sep; 96(9):1569-1572. PubMed ID: 28573313
[No Abstract] [Full Text] [Related]
4. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.
De Smedt R; Morscio J; Reunes L; Roels J; Bardelli V; Lintermans B; Van Loocke W; Almeida A; Cheung LC; Kotecha RS; Mansour MR; Uyttebroeck A; Vandenberghe P; La Starza R; Mecucci C; Lammens T; Van Roy N; De Moerloose B; Barata JT; Taghon T; Goossens S; Van Vlierberghe P
Blood; 2020 May; 135(19):1685-1695. PubMed ID: 32315407
[TBL] [Abstract][Full Text] [Related]
5. Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth.
Lu H; Kojima K; Battula VL; Korchin B; Shi Y; Chen Y; Spong S; Thomas DA; Kantarjian H; Lock RB; Andreeff M; Konopleva M
Ann Hematol; 2014 Mar; 93(3):485-492. PubMed ID: 24154679
[TBL] [Abstract][Full Text] [Related]
6. Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia.
Kantarjian HM
Clin Adv Hematol Oncol; 2019 May; 17(5):268-270. PubMed ID: 31188803
[No Abstract] [Full Text] [Related]
7. New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models.
Hixon JA; Andrews C; Kashi L; Kohnhorst CL; Senkevitch E; Czarra K; Barata JT; Li W; Schneider JP; Walsh STR; Durum SK
Leukemia; 2020 Jan; 34(1):35-49. PubMed ID: 31439943
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
Ribera JM
Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
[TBL] [Abstract][Full Text] [Related]
9. Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.
Paul S; Rausch CR; Kantarjian H; Jabbour EJ
Future Oncol; 2017 Oct; 13(25):2233-2242. PubMed ID: 28776425
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management.
Rausch CR; Jabbour EJ; Kantarjian HM; Kadia TM
Cancer; 2020 Mar; 126(6):1152-1160. PubMed ID: 31794095
[No Abstract] [Full Text] [Related]
11. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
[TBL] [Abstract][Full Text] [Related]
12. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
Reusch U; Harrington KH; Gudgeon CJ; Fucek I; Ellwanger K; Weichel M; Knackmuss SH; Zhukovsky EA; Fox JA; Kunkel LA; Guenot J; Walter RB
Clin Cancer Res; 2016 Dec; 22(23):5829-5838. PubMed ID: 27189165
[TBL] [Abstract][Full Text] [Related]
13. Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia.
Tanaka H; Fujiwara H; Ochi F; Tanimoto K; Casey N; Okamoto S; Mineno J; Kuzushima K; Shiku H; Sugiyama T; Barrett AJ; Yasukawa M
Clin Cancer Res; 2016 Sep; 22(17):4405-16. PubMed ID: 27091408
[TBL] [Abstract][Full Text] [Related]
14. Cytoplasmic CD3 Positivity as the Only Clue for the Diagnosis of T-Acute Lymphoblastic Leukemia With Cutaneous Deposits: A Case Report.
Elbendary A; Abdelkader HA; Abdel-Galeil Y; El-Mofty M; Sultan AM; Elkomi AS; Abdel-Halim MRE
Am J Dermatopathol; 2020 Jan; 42(1):43-45. PubMed ID: 31124883
[No Abstract] [Full Text] [Related]
15. Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia.
Litzow MR
Am Soc Clin Oncol Educ Book; 2013; ():294-9. PubMed ID: 23714527
[TBL] [Abstract][Full Text] [Related]
16. Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin.
Kantarjian H; Jabbour E
Am Soc Clin Oncol Educ Book; 2018 May; 38():574-578. PubMed ID: 30231308
[TBL] [Abstract][Full Text] [Related]
17. Terminal deoxynucleotidyl transferase (TdT)-negative T-cell lymphoblastic lymphoma with loss of the T-cell lineage-specific marker CD3 at relapse: a rare entity with an aggressive outcome.
Hassan M; Abdullah HMA; Wahid A; Qamar MA
BMJ Case Rep; 2018 Jun; 2018():. PubMed ID: 29884716
[TBL] [Abstract][Full Text] [Related]
18. The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis.
Lenk L; Baccelli I; Laqua A; Heymann J; Reimer C; Dietterle A; Winterberg D; Mary C; Corallo F; Taurelle J; Narbeburu E; Neyton S; Déramé M; Pengam S; Vogiatzi F; Bornhauser B; Bourquin JP; Raffel S; Dovhan V; Schüler T; Escherich G; den Boer ML; Boer JM; Wessels W; Peipp M; Alten J; Antić Ž; Bergmann AK; Schrappe M; Cario G; Brüggemann M; Poirier N; Schewe DM
Blood; 2024 Jun; 143(26):2735-2748. PubMed ID: 38518105
[TBL] [Abstract][Full Text] [Related]
19. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens.
Jain P; Kantarjian H; Jain N; Short NJ; Yin CC; Kanagal-Shamanna R; Khoury J; Konopleva M; Sasaki K; Kadia TM; Garris R; Pierce S; Estrov Z; Wierda W; Cortes J; O'Brien S; Ravandi F; Jabbour E
Am J Hematol; 2017 Oct; 92(10):E595-E597. PubMed ID: 28646517
[No Abstract] [Full Text] [Related]
[Next] [New Search]
